The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration

Antzeko izenburuak

• Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009
  nork: Tanaka, Nobumichi, et al.
  Argitaratua: (2013)
• The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
  nork: Tanaka, Nobumichi, et al.
  Argitaratua: (2015)
• Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
  nork: Tanaka Nobumichi, et al.
  Argitaratua: (2012-09-01)
• Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
  nork: Inoue Takeshi, et al.
  Argitaratua: (2013-01-01)
• Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
  nork: Tanaka, Nobumichi, et al.
  Argitaratua: (2012)